Peptide therapy claims on TikTok: separating hype from evidence

What did @vitality.and.wellness actually say?

The creator laid out two peptide mistakes: taking "not enough" so it "won't work," and taking "too much" where you're "not getting anything out of that excess." That's it. No specific peptides named, no doses given, no mechanism explained. The entire claim rests on the idea that peptide dosing follows a dose-response curve with a ceiling or saturation point. It's a real concept, but the way it was presented strips out so much context it becomes nearly useless as guidance.

To be fair, the creator didn't prescribe anything or name specific compounds. That restraint is worth noting. But vague advice presented with confidence can mislead people into thinking they now know something actionable, when they don't.

Does the science back this up?

Partially, yes. Peptides do follow dose-response relationships, and receptor saturation is a documented phenomenon. But the claim that "too much" means you get nothing extra is an oversimplification that collapses important distinctions between peptide classes.

Growth hormone secretagogues like ipamorelin and CJC-1295 operate through pituitary receptors that can become desensitized with overuse. Research by Sigalos and Pastuszak (2018, Sexual Medicine Reviews) noted that supraphysiologic stimulation of GH-releasing pathways does not proportionally increase GH output and may blunt receptor sensitivity over time. For tissue-repair peptides like BPC-157, rat studies (Sikiric et al., 2018, Current Pharmaceutical Design) show dose-dependent effects, but most human dosing is extrapolated from animal data with significant uncertainty. The creator's framing treats all peptides as one category, which they are not. Different peptides hit different receptors with different saturation kinetics.

What did they get wrong (or right)?

They got the general principle right: underdosing peptides is a real issue, and receptor saturation does set a practical ceiling on benefit for certain compounds. Credit where it's due.

What they got wrong is the framing. Saying you get "nothing" from excess dosing skips over the more important concern: potential side effects at higher doses. Higher doses of growth hormone secretagogues are associated with increased cortisol, prolactin, and water retention, per data reviewed by Walker (2006, Growth Hormone and IGF Research). For peptides like MK-677, which mimics ghrelin, higher doses raise insulin resistance and appetite dysregulation risk (Nass et al., 2008, Annals of Internal Medicine). "Nothing out of that excess" is not the accurate downside. The accurate downside is that excess dosing can cause measurable harms, not just wasted product.

• Correct: dose-response curves exist for peptides
• Correct: underdosing is a common and real problem
• Wrong: excess dosing means wasted money only, not potential adverse effects
• Missing: different peptides have entirely different saturation profiles

What should you actually know?

Peptide dosing is genuinely complicated, and that complication is doing a lot of work that a 20-second TikTok cannot carry. The "sweet spot" concept is real in pharmacology, but finding it for any specific peptide requires knowing the compound, the individual's baseline hormone levels, and the therapeutic goal. None of that is one-size-fits-all.

More importantly, most peptides discussed in wellness content, including BPC-157, TB-500, CJC-1295, and ipamorelin, are not FDA-approved for human use. Compounded versions exist through licensed providers operating under specific regulatory frameworks, but their dosing guidance comes from clinical judgment and limited human trial data, not large randomized controlled trials. Anyone telling you there's a clean answer to "how much is enough" is filling a gap that the published science hasn't closed yet.

If you're considering peptide therapy, the right starting point is a provider who can assess your labs and goals, not a general rule about too little versus too much.